Normally slow-moving Cigna Corporation (CI), first discussed here on May 28, 2009 at a price of $21.89, has been on the move, rising $7 from about $35 to $42, and I obviously still like the shares at this juncture.

Cigna's should post a 1-3% revenue gain in 2011, after a 17% increase in 2010. CI's health care unit should lead the way, with the unit's revenue advancing on both increased subscribers and higher premiums. What's more, the retention rates for new products for individual, small-group, and middle market customers have been impressive. Products for national accounts, however, less-impressive.

Insurance giant Aetna Inc. (AET) will be reporting its fourth quarter earnings Friday before the market opens, with analysts expecting to see a strong quarter for the company.

Going into tomorrow's earnings report, analysts are expecting to see Aetna report earnings of $0.62 per share, up from $0.40 during the same period last year.

Analyst Upgrades

• Exxon Mobil (XOM) and BB&T (BBT) to outperform from perform at Oppenheimer.
• D.R. Horton (DHI) upgraded to outperform from market perform at Wells Fargo.
• Meritage Homes (MTH), Old Dominion Freight (ODFL) and Heartland Payment (HPY) to outperform from market perform at Wells Fargo.
• Toll Brothers (TOL) to overweight from equal weight at Barclays.
• Hershey (HSY) to buy from neutral at Janney Capital.
• UnitedHealth (UNH), Cigna (CI) and Allscripts (MDRX) to buy from hold at Deutsche Bank.
• Nationwide Health (NHP) to outperform from market perform at JMP Securities.
• Reynolds American (RAI) to buy from neutral at UBS.
• Adtran (ADTN), PG&E (PCG) and Wisconsin Energy (WEC) to overweight from equal weight at Morgan Stanley.

Insurer Cigna Corp. (CI), first discussed here on May 28, 2009 at a price of $21.89, has moved out of a trough recorded this summer, and I obviously still like the shares at this juncture.

Cigna should post a 1-3% revenue gain in 2011, after a likely double-digit increase in 2010. CI's health care unit should lead the way, with the unit's revenue advancing on both increased subscribers and higher premiums. What's more, the retention rate for new products for individual, small-group, and middle market customers has been impressive; products for national accounts, less-impressive.

Analyst Upgrades

• Goldman upgraded Eaton (ETN) to conviction buy from neutral.
• AECOM Technology (ACM) was upgraded to outperform from neutral at Macquarie.
• Piper Jaffray upgraded Hologic (HOLX), Gen-Probe (GPRO) and Qiagen (QGEN) to overweight from neutral.
• GeoMet (GMET) was upgraded to accumulate from neutral at Global Hunter.
• Accretive Health (AH) was upgraded to outperform from neutral at RW Baird.
• Morgan Stanley upgraded Reinsurance Group (RGA) to overweight from equal weight.
• BofA/Merrill upgraded Clearwire (CLWR) to neutral from underperform.

Here are some highlights from this past week's earnings coverage on BloggingStocks:

• Blockbuster Inc. (BBI) Q1 net loss was in line with estimates and same-store sales declined, shares also fell.
• CA Inc. (CA) shares sold off on high volume following the Q4 earnings miss and disappointing guidance.
• Cigna Corp. (CI) reported better-than-expected Q1 earnings and higher revenue, and reaffirmed its full-year outlook.
• Cisco Systems Inc. (CSCO) beat Q3 earnings and revenue expectations in the "strongest quarter in our history."
• Dean Foods Co. (DF) lower Q1earnings beat analysts' estimates, but shares fell on heavy volume afterward.
• Denny's Corp. (DENN) bested consensus estimates and year-ago EPS by a penny, but said same-store sales fell.

Insurer CIGNA Corporation (CI) posted solid first quarter earnings of $1.01 per share, excluding items, compared to the Thomson/Reuters First Call estimate of 90 cents. So far, investors are more than satisfied. Cigna's shares rose about 75 cents after the earnings release, and recently have recovered nearly all of the ground lost during the May 6 "flash crash." On Tuesday afternoon shares rose 87 cents to $33.52. Cigna earned 76 cents per share a year ago.

Cigna, which benefited from a strong international performance, also kept its 2010 earnings guidance the same, with the company seeing full-year EPS of $3.75 to $4.15, compared to the First Call estimate of $4.08. First Call also expects CI to earn $4.36 in 2011.

Humana Inc. (HUM), whose colleagues include Aetna Inc. (AET) and CIGNA Corporation (CI), reported Q1 earnings earlier today. The health insurer isn't doing so well, unfortunately. In late trading, shares were down almost 3% to $43.73. Volume is above the norm, as you might expect.

I've covered many stocks that are near their 52-week highs, but this one doesn't fall into such a desirable category. Alas, the 52-week high on the shares stands at $52.66. And, as you can see from the following one-year chart, the stock began its pullback after it topped out in January. Since then, things haven't been too exciting.

Humana Inc. (HUM), who's shares (like other insurers') received a nice bump from the outcome of the special election in Massachusetts, is scheduled to discuss its fourth-quarter 2009 financial results and 2010 guidance in a conference call Monday, Feb. 1, at 9:00 AM (ET). A live webcast of the call will be available at the company's website.

During the three months that ended in December, Humana expanded its Medicare offerings and launched a share buyback program and a social media tool. Analysts surveyed by Thomson Reuters are looking for earnings for that period to have grown 27.7% year over year to $1.48 cents per share. Revenue for the quarter is expected to be 4.0% higher to $7.8 billion.

Analyst Upgrades

• Jefferies upgraded Citrix Systems (CTXS) to buy from hold and raised its target to $48 from $43, citing VMware's (VMW) strong Q4 report and survey results that indicate continued strength for Citrix.
• Citigroup upgraded Amylin Pharmaceuticals (AMLN) to buy from hold on confidence the company's LAR drug will be approved following the approval of Novo Nordisk's (NVO) Victoza. Citi raised its target price for Amylin shares to $27 from $4.
• Baird upgraded Texas Instruments (TXN) to outperform from neutral and raised its target to $30 from $28. The firm believes it is too early to take profits in Texas Instruments and notes that checks continue to indicate a continued recovery in end-demand.
• Lexmark (LXK) was upgraded to overweight from equal weight at Barclays.
• Salix (SLXP) was upgraded to outperform from perform at Oppenheimer.
• Plexus (PLXS) was lifted to outperform from neutral at Credit Suisse.

President Obama started an intense debate in recent months about national health care. People are concerned about how to pay for the high cost of health care in America and feel it is just too expensive. There has to be a better way!

I like oranges and I grew up in Wisconsin, but in January oranges do not grow very well in Wisconsin. I don't know why -- I am not a horticulturalist -- but maybe it's the lack of sunlight, hard frozen tundra, blowing snow or temperatures of 25 below zero. We could spend a long time pointlessly debating the actual reason.

A late-May conclusion arguing that institutional investors had started to re-commit to Cigna Corp., due to its constructive, staircase chart, virtually no breaches of the 50-day moving average, and adequate earnings outlook, has so far proved to be on-the-mark.

Hence, I'm reiterating my Buy rating for Cigna Corp. (NYSE: CI), first recommended on May 28, 2009 at a price of $21.89. If you bought CI then, you're up about 45%.

Readers of this space know that the bias favors conservative-to-moderate risk companies with demonstrated business models. Moreover, the methodology emphasizes fundamentals, preferably supported by technical indicators.

But every once in a while, the technicals take precedence, particularly in an oversold stock in an out-of-favor sector where the 50-day moving average comes in to play. Cigna (NYSE: CI) is one such case study.

Analyst upgrades:

• UBS upgraded Target (NYSE: TGT) to Buy from Neutral and raised its price target to $52 from $45 citing reduced inventories, some credit stability, and an improved back-to-school period.
• Credit Suisse said concerns regarding Safeway's (NYSE: SWY) price position are overblown and that earnings risk is limited. The firm upgraded shares to Outperform from Neutral and raised the target price to $25 from $22.
• Oppenheimer upgraded Canadian Solar (NASDAQ: CSIQ) to Outperform from Perform as it believes the story is underappreciated following the recent sector rally. The firm has a $14 price target on the stock.
• CME Group (NASDAQ: CME) was upgraded to buy from Neutral at Goldman.
• Freeport McMoRan (NYSE: FCX) was upgraded to Overweight from Neutral at JP Morgan.
• Gilead Sciences (NASDAQ: GILD) was upgraded to Buy from Neutral at FTN Equity.

If you've been watching earnings this past week, or if you read last week's Week in Preview, then this coming week may leave you feeling a bit like Bill Murray in Groundhog's Day. That is, again analysts surveyed by Thomson Reuters expect earnings declines to be more frequent and deeper than earnings gains.

Motorola Inc. (NYSE: MOT), Dow Chemical Co. (NYSE: DOW), Anadarko Petroleum Corp. (NYSE: APC), IAC Interactivecorp (NASDAQ: IACI), Moody's Corp. (NYSE: MCO), Elizabeth Arden Inc. (NASDAQ: RDEN), Devon Energy Corp. (NYSE: DVN), Diebold Inc. (NYSE: DBD), Tyco International Ltd. (NYSE: TYC), United Parcel Service (NYSE: UPS), Cisco Systems Inc. (NASDAQ: CSCO), Polo Ralph Lauren Corp. (NYSE: RL), ITT Corp. (NYSE: ITT), and Walt Disney Co. (NYSE: DIS) are scheduled to report quarterly results this week, and they're all expected to report double-digit declines in earnings.

But again this week, let's take a look who Wall Street feels may have done well in the past quarter.